Lymphokine- activated killer (LAK) cells were chosen as effector cells because they are a clinically applicable heterogeneous population of NKG2D+, interleukin 2 (IL-2) activated NK, NKT and T cells32 and we are currently conducting a clinical trial based on the antibody targeted delivery of IL-2 to the MCC tumor microenvironment (www.immomec.com). This evidence concerns the gene KLRK1 and neoplasm.